Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Incyte finally has some good news to share about one drug it’s discovered that’s not Jakafi — albeit one that doesn’t belong to it anymore.
FDA regulators have accepted capmatinib, an orphan and “breakthrough” MET inhibitor, for priority review. The honor technically goes to Novartis, which licensed worldwide development and commercialization rights to the drug back in 2009.
But that didn’t stop Incyte from bragging about it in a release, reminding investors that if everything goes well, it’s eligible for $500 million-plus in milestones as well as royalties up to 14% of global sales.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters